Leukemia Research
Volume 33, Issue 12 , Pages 1599-1603 , December 2009

Characterization of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in Shanghai, China: Molecular and cytogenetic characteristics, IgV gene restriction and hypermutation patterns

  • Richard D. Irons

      Affiliations

    • Fudan-Cinpathogen Clinical and Molecular Research Center, Institutes of Biomedical Sciences, Fudan University, Shanghai, China
    • Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Denver, CO, USA
    • Department of Pathology, School of Medicine, University of Colorado Denver, CO, USA
    • Corresponding Author InformationCorresponding author at: Fudan-Cinpathogen Clinical and Molecular Research Center, Institutes of Biomedical Sciences, Fudan University, Shanghai, China. Tel.: +1 303 381 2543; fax: +1 303 724 3673.
    • ,
  • Anh Le

      Affiliations

    • Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Denver, CO, USA
    • ,
  • Liming Bao

      Affiliations

    • Fudan-Cinpathogen Clinical and Molecular Research Center, Institutes of Biomedical Sciences, Fudan University, Shanghai, China
    • Division of Human Genetics, Cincinnati Children's Hospital Medical Center and College of Medicine, University of Cincinnati, OH, USA
    • ,
  • Xiongzeng Zhu

      Affiliations

    • Department of Pathology, Cancer Hospital, Fudan University, Shanghai, China
    • ,
  • John Ryder

      Affiliations

    • Department of Pathology, School of Medicine, University of Colorado Denver, CO, USA
    • ,
  • Xiao Qin Wang

      Affiliations

    • Fudan-Cinpathogen Clinical and Molecular Research Center, Institutes of Biomedical Sciences, Fudan University, Shanghai, China
    • Huashan Hospital, Fudan University, Shanghai, China
    • ,
  • Meirong Ji

      Affiliations

    • Huashan Hospital, Fudan University, Shanghai, China
    • ,
  • Yan Chen

      Affiliations

    • Fudan-Cinpathogen Clinical and Molecular Research Center, Institutes of Biomedical Sciences, Fudan University, Shanghai, China
    • ,
  • Xichun Wu

      Affiliations

    • Division of Human Genetics, Cincinnati Children's Hospital Medical Center and College of Medicine, University of Cincinnati, OH, USA
    • ,
  • Guowei Lin

      Affiliations

    • Huashan Hospital, Fudan University, Shanghai, China

Received 22 December 2008 ,Revised 22 December 2008 ,Accepted 29 December 2008.

References 

  1. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. Journal of Clinical Oncology. 1999;17:3835–3849
  2. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. New England Journal of Medicine. 2005;352:804–815
  3. Boggs DR, Chen SC, Zhang ZN, Zhang A. Chronic lymphocytic leukemia in China. American Journal of Hematology. 1987;25:349–354
  4. Gross S, Zhu X, Bao L, Ryder L, Le A, Chen Y, et al. A prospective study of 728 cases of non-Hodgkin lymphoma from a single laboratory in Shanghai, China. International Journal of Hematology. 2008;88(2):165–173
  5. Byrd JC, Smith L, Hackbarth ML, Flinn IW, Young D, Proffitt JH, et al. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Research. 2003;63:36–38
  6. Juliusson G, Oscier DG, Fitchett M, Ross FM, Stockdill G, Mackie MJ, et al. Prognostic subgroups in B-Cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. New England Journal of Medicine. 1990;323:720–724
  7. Neilson JR, Auer R, White D, Bienz N, Waters JJ, Whittaker JA, et al. Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival. Leukemia. 1997;11:1929–1932
  8. Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood. 2004;103:1202–1210
  9. Doneda L, Castorina P, Tedeschi A, Intropido L, Morra E, Montillo M, et al. Multicolor FISH in chronic lymphocytic leukemia. An interphase study of patients with early-onset disease. Cancer Genetics and Cytogenetics. 2001;125:63–69
  10. Garcia-Marco JA, Price CM, Catovsky D. Interphase cytogenetics in chronic lymphocytic leukemia. Cancer Genetics and Cytogenetics. 1997;94:52–58
  11. Arif M, Tanaka K, Asou H, Ohno R, Kamada N. Independent clones of trisomy 12 and retinoblastoma gene deletion in Japanese B cell chronic lymphocytic leukemia detected by fluorescence in situ hybridization. Leukemia. 1995;9:1822–1827
  12. Chang YH, Park J, Kim HC, Chun HK, Kim YR, Kim M, et al. Korean patients with chronic lymphocytic leukemia show the similar types of chromosomal aberrations as those in Europe and North America. Leukemia Research. 2006;30:695–699
  13. Kwong YL, Pang J, Ching LM, Liu HW, Liang RH, Chan LC. Trisomy 12 in chronic lymphocytic leukemia. An interphase cytogenetic study by fluorescence in situ hybridization. Cancer Genetics and Cytogenetics. 1994;72:83–85
  14. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848–1854
  15. Tobin G, Rosen A, Rosenquist R. What is the current evidence for antigen involvement in the development of chronic lymphocytic leukemia?. Hematological Oncology. 2006;24:7–13
  16. Fais F, Ghiotto F, Hashimoto S, Sellars B, Valetto A, Allen SL, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. Journal of Clinical Investigation. 1998;102:1515–1525
  17. Hamblin T. Prognostic factors in chronic lymhocytic leukemia. Leukemia & Lymphoma. 2006;47:2261–2262
  18. Jaffe E, Harris N, Stein H, Vardiman J. In:  Kleihues P,  Sobin LH editor. World Health Organization Classification of Tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001;
  19. Mitelman F. In:  Mitelman F editors. An international system for human cytogenetic nomenclature: Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature, Memphis, TN, October 1994. New York: Karger; 1995;
  20. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. New England Journal of Medicine. 2004;350:1828–1837
  21. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219–234
  22. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O’Brien S, et al. National Cancer Institute-Sponsored Working Group Guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990–4997
  23. Murray F, Darzentas N, Hadzidimitriou A, Tobin G, Boudjogra M, Scielzo C, et al. Stereotyped Patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood. 2008;111:1524–1533
  24. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. New England Journal of Medicine. 2000;343:1910–1916
  25. Hu X, Wang X, Bao L, Shui R, Zhu X, Irons RD, et al. Cytogenetic and interphase FISH studies in the diagnosis of malignant lymphomas. Chinese Journal of Oncology (Zhonghua Zhong Liu Za Zhi). 2007;29:45–48
  26. Chang B, Casali P. The Cdr1 sequences of a major proportion of human germline Ig Vh genes are inherently susceptible to amino acid replacement. Immunology Today. 1994;15:367–373
  27. Nelson BP, Gupta R, Dewald GW, Paternoster SF, Rosen ST, Peterson LC. Chronic lymphocytic leukemia FISH panel: impact on diagnosis. American Journal of Clinical Pathology. 2007;128:323–332
  28. Ghia P, Stamatopoulos K, Belessi C, Moreno C, Stella S, Guida G, et al. Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. Blood. 2005;105:1678–1685
  29. Koiso H, Yamane A, Mitsui T, Matsushima T, Tsukamoto N, Murakami H, et al. Distinctive immunoglobulin VH gene usage in Japanese patients with chronic lymphocytic leukemia. Leukemia Research. 2006;30:272–276
  30. Herve M, Xu K, Ng YS, Wardemann H, Albesiano E, Messmer BT, et al. Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. Journal of Clinical Investigation. 2005;115:1636–1643
  31. Naylor M, Capra JD. Mutational status of Ig VH genes provides clinically valuable information in B-cell chronic lymphocytic leukemia. Blood. 1999;94:1837–1839
  32. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V Gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840–1847
  33. Shankey TV, Forman M, Scibelli P, Cobb J, Smith CM, Mills R, et al. An optimized whole blood method for flow cytometric measurement of Zap-70 protein expression in chronic lymphocytic leukemia.. Cytometry Part B Clinical Cytometry. 2006;70:259–269

PII: S0145-2126(09)00005-8

doi: 10.1016/j.leukres.2008.12.021

Leukemia Research
Volume 33, Issue 12 , Pages 1599-1603 , December 2009

Article Tools

* Image Usage & Resolution